STERIS plc FY 2026 10-K, explained in plain English
Key financials — as reported
| Total revenue | $5.9B |
| Gross margin | 44.2% |
| Operating income | $1.1B |
| Net income | $782.3M |
| Diluted EPS | $7.93 |
| Cash & equivalents | — not reported |
| Total assets | $10.7B |
| Long-term debt | $1.8B |
Key takeaway
STERIS now operates in three reportable segments—Healthcare, AST, and Life Sciences—after divesting its Dental segment in fiscal 2025, which is now shown as discontinued operations.
🔒 4 more takeaways in the full analysis
Beneath the surface
Total debt of $1.93 billion combined with limited cash disclosure in the provided facts suggests investors should check the balance sheet cash position separately, as no cash/marketable securities figure is included in this fact set to calculate true net debt.
🔒 3 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for STE.
Read the full analysis free Free account · 5 full analyses included · no card required